Company Overview
Snapshot
Founded in November 2018 by Tsvi Dahan and Meir Dahan, Hila Pharma operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on developing products for molecular imaging. In September 2020, the company, also known as ProtectAir, developed an air-purifier capable of neutralizing over 99% of airborne viruses and bacteria, including COVID-19.
Business overview
Hila Pharma develops molecular imaging products designed to enable precise diagnoses and enhance therapy planning. The company's core technology focuses on nuclear medicine, offering a comprehensive range of products for both diagnostic and therapeutic applications. These include SPECT and PET diagnostic products, MRI contrast agents, and nuclear therapeutic materials like LU-177. Hila Pharma serves markets within the Health Tech & Life Sciences sector, specifically targeting medical devices, diagnostics, and pharmaceutical biotechnology.
Strategic signal
In September 2020, Hila Pharma, operating under the name ProtectAir, announced the development of an air-purifier that neutralizes over 99% of airborne viruses and bacteria, including COVID-19. This innovation, which utilizes chlorine dioxide, has received regulatory approvals and is securing global distribution agreements. This signals the company's capability to leverage its scientific expertise for broader public health applications beyond its core molecular imaging focus, indicating potential for diversified revenue streams and market expansion into air purification solutions for various public and private environments.
Log in to access full profile ›Company Intelligence Q&A
- What is Hila Pharma's primary focus?
- Hila Pharma's primary focus is on developing products for molecular imaging to facilitate precise diagnoses and improve therapy planning, particularly within the field of nuclear medicine.
- When was Hila Pharma founded and by whom?
- Hila Pharma was founded in November 2018 by co-founders Tsvi Dahan and Meir Dahan.
- What significant product development did Hila Pharma (ProtectAir) announce in September 2020?
- In September 2020, Hila Pharma, under its ProtectAir brand, announced the development of an air-purifier capable of neutralizing over 99% of airborne viruses and bacteria, including COVID-19. The device releases chlorine dioxide at a low concentration.
- What types of products does Hila Pharma offer in nuclear medicine?
- Hila Pharma offers a broad range of products for nuclear medicine, including SPECT and PET diagnostic products, MRI contrast agents, and several nuclear therapeutic materials such as LU-177.
- What is the current employee size of Hila Pharma?
- Hila Pharma currently has 1–10 employees.